A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 23 Jan 2017 Results assessing the feasibility and clinical outcome with intermittent sunitinib dosing in patients with metastatic renal cell carcinoma, published in the Journal of Clinical Oncology.
- 11 Jul 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.